1. Expression of the immune checkpoint receptor TIGIT in Hodgkin's lymphoma.
- Author
-
Li, Wenchao, Blessin, Niclas C., Simon, Ronald, Kluth, Martina, Fischer, Kristine, Hube-Magg, Claudia, Makrypidi-Fraune, Georgia, Wellge, Björn, Mandelkow, Tim, Debatin, Nicolaus F., Pott, Laura, Höflmayer, Doris, Lennartz, Maximilian, Sauter, Guido, Izbicki, Jakob R., Minner, Sarah, Büscheck, Franziska, Uhlig, Ria, Dum, David, and Krech, Till
- Subjects
- *
HODGKIN'S disease , *T cell receptors , *HODGKIN'S disease treatment , *IMMUNOTHERAPY , *IMMUNOHISTOCHEMISTRY , *CELL physiology , *CELL receptors , *GENES , *T cells - Abstract
Hodgkin's lymphoma (HL) is characterized by a high background of inflammatory cells which play an important role for the pathogenesis of the disease. T cell immunoreceptor with Ig and ITIM domains (TIGIT) is an inhibitory immune checkpoint receptor and a putative target for novel immunotherapies. To study patterns of TIGIT expression in the T cell background surrounding malignant cells including Hodgkin cells, Reed-Sternberg cells and histiocytic cells, a microenvironment (ME) tissue microarray (TMA) was constructed from tissue punches measuring 2 mm in diameter obtained from formalin-fixed tissue samples of Hodgkin's lymphoma lymph nodes (n = 40) and normal human tonsil (n = 2). The ME-TMA was stained by brightfield and fluorescence multiplex immunohistochemistry (IHC) to evaluate expression levels of TIGIT and PD-1 as well as standard lymphocyte markers (CD3, CD8, CD4, FOXP3) in the lymphocytic background. All analyzed cases of HL contained 9-99% (median: 86%) of TIGIT+ lymphoid cells. In general, TIGIT localized to the same cells as PD-1. Strikingly, expression levels of TIGIT and PD-1 were highly variable among the analyzed samples. Highest levels of TIGIT and PD-1 were found in one sample of nodular lymphocytic-predominant HL (NLPHL). In conclusion, TIGIT expression is highly variable between patients with Hodgkin's lymphoma. Our results encourage further studies evaluating the role of TIGIT as a target for immunotherapies in Hodgkin's lymphoma. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF